- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mineralys Therapeutics Inc (MLYS)
"Mineralys Therapeutics Inc stock price live, this page displays NASDAQ MLYS stock exchange data. View the MLYS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Mineralys Therapeutics Inc real time stock price chart below.
What Is the Mineralys Therapeutics Inc Stock Price Today?
The Mineralys Therapeutics Inc stock price today is 15.30.
What Is the Stock Symbol for Mineralys Therapeutics Inc?
The stock symbol for Mineralys Therapeutics Inc is ""MLYS.""
What Stock Exchange Does Mineralys Therapeutics Inc Trade On?
Mineralys Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Mineralys Therapeutics Inc a Good Stock to Buy?
Determining whether Mineralys Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MLYS quote. (ISIN: US6031701013)"
What Is the Mineralys Therapeutics Inc Stock Price Today?
The Mineralys Therapeutics Inc stock price today is 15.30.
What Is the Stock Symbol for Mineralys Therapeutics Inc?
The stock symbol for Mineralys Therapeutics Inc is ""MLYS.""
What Stock Exchange Does Mineralys Therapeutics Inc Trade On?
Mineralys Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Mineralys Therapeutics Inc a Good Stock to Buy?
Determining whether Mineralys Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MLYS quote. (ISIN: US6031701013)"
NASDAQ
Currency in USD
15.30
+0.29(+1.93%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.74
15.40
52 wk Range
8.24
18.38
MLYS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MLYS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.7415.40
52 wk Range
8.2418.38
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MLYS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
40.00
Upside
+161.44%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Mineralys Therapeutics Inc Company Profile
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company’s clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mineralys Therapeutics Inc Earnings Call Summary for Q1/2025
- Mineralys beats Q1 2025 EPS expectations with -$0.79 vs -$1.08 forecast, stock rises 1.93% in aftermarket trading to $15.3
- Net loss increased to $42.2M from $31.5M in Q1 2024 due to higher R&D and G&A expenses; cash position strong at $343M
- Lorundrostat shows promising results in pivotal trials; NDA submission planned after FDA pre-NDA meeting in Q4 2025
- Company targets 47,000 physicians for initial promotion of Lorundrostat, anticipating potential FDA approval
- Management emphasizes aldosterone's role in hypertension treatment and importance of addressing extreme blood pressure spikes
Last Updated: 2025/05/12, 23:28
Read Full TranscriptCompare MLYS to Peers and Sector
Metrics to compare | MLYS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMLYSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.2x | −3.4x | −0.5x | |
PEG Ratio | 0.06 | 0.00 | 0.00 | |
Price/Book | 5.2x | 1.8x | 2.6x | |
Price / LTM Sales | - | 27.2x | 2.9x | |
Upside (Analyst Target) | 185.1% | 235.7% | 53.0% | |
Fair Value Upside | Unlock | −1.4% | 8.9% | Unlock |
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 40.00
(+161.44% Upside)
Earnings
Latest Release
May 12, 2025
EPS / Forecast
-0.79 / -1.08
Revenue / Forecast
-- / --
FAQ
What Is the Mineralys Therapeutics (MLYS) Stock Price Today?
The Mineralys Therapeutics stock price today is 15.30
What Stock Exchange Does Mineralys Therapeutics Trade On?
Mineralys Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Mineralys Therapeutics?
The stock symbol for Mineralys Therapeutics is "MLYS."
What Is the Mineralys Therapeutics Market Cap?
As of today, Mineralys Therapeutics market cap is 973.79M.
What Is Mineralys Therapeutics's Earnings Per Share (TTM)?
The Mineralys Therapeutics EPS (TTM) is -3.66.
When Is the Next Mineralys Therapeutics Earnings Date?
Mineralys Therapeutics will release its next earnings report on 11 May 2025.
From a Technical Analysis Perspective, Is MLYS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.